Amgen Inc. saw a decline in its stock after the results of a yearlong trial for its experimental obesity treatment, MariTide. The trial involved 592 obese patients, including those with diabetes, and focused on the amount of weight lost as the main endpoint.

The trial showed that participants experienced a weight loss of up to 20%. However, despite this significant weight loss, investor expectations were not met, leading to disappointment in the market. The trial also evaluated the duration between injections and the continued weight loss effects. Unfortunately, approximately 11% of participants discontinued treatment due to adverse events.